Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective Real-world Study of Abemaciclib Plus Endocrine Therapy vs Endocrine Monotherapy in HR-positive, HER2-negative Advanced/Metastatic Breast Cancer
jRCT1070250028Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to Next Treatment (TTNT) - ABE+ET combination group, C10 cohort. Started Jun 2025; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT1070250028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1070250028.